Risk factor
Poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases. The company's products include osteoarthritis treatment products, osteoporosis treatment preparations, iron supplement, urinary system treatment products, expectorants/mucolytic agents, anti-hypertensive preparations, and anti-diabetic preparations, anti-adhesion systems, pellefeel wound care systems, Philips non-invasive ventilators, and others, as well as medical devices and functional foods. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of 4169.TWO is 113 and suggests 34% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to
Buy
Sell